Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases
- PMID: 26284597
- PMCID: PMC5302020
- DOI: 10.1053/j.gastro.2015.08.006
Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases
Abstract
The microbiome plays multifaceted roles in the pathogenesis of inflammatory bowel diseases (IBD). Accordingly, the clinical challenge of patient heterogeneity in disease phenotype and response to treatment should in part be addressed by biomarkers that detect the host response to microbiota, and the levels of microbial taxa and products eliciting the host response in susceptible individuals. Molecular analysis has revealed much evidence for microbial taxonomic membership and microbial products in association with IBD, but their utility as clinical biomarkers is still in its infancy. A rich area of progress has been the development and validation of host serologic microbial biomarkers, which have achieved a distinctive position in the diagnosis and prognosis in IBD, and as a template for defining other categories of microbial biomarkers in disease state and phenotype.
Keywords: Gastrointestinal Disease; Genetics; Genomics; Immunology.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
of Competing Interests: Marla Dubinsky: Consultant, Prometheus Laboratories Inc. Jonathan Braun: Consultant, Janssen Pharmaceuticals, Inc.; Eli Lilly and Company, Inc.
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
